<DOC>
	<DOCNO>NCT01624480</DOCNO>
	<brief_summary>This study evaluate pharmacokinetics , pharmacodynamics , safety single multiple dos armodafinil ( 50 , 100 , 150 mg/day ) child adolescent excessive sleepiness associate narcolepsy .</brief_summary>
	<brief_title>Study Evaluate Pharmacokinetics , Pharmacodynamics , Safety Armodafinil Children Adolescents With Excessive Sleepiness Associated With Narcolepsy</brief_title>
	<detailed_description />
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<criteria>Written inform consent obtain patient 's parent legal guardian write assent obtain patient . The patient male female 6 17 year age body mass index ( BMI ) equal great 10th percentile age gender , inclusive . The patient diagnosis narcolepsy cataplexy narcolepsy without cataplexy accord criterion establish International Classification Sleep Disorders ( ICSD ) 2 narcolepsy . The patient clinically significant uncontrolled medical condition ( treat untreated ) narcolepsy . The patient clinically significant deviation normal ECG , physical examination vital sign finding , determine investigator medical monitor . The patient pregnant lactating . ( Any patient become pregnant study withdrawn study ) The patient history seizure , include febrile seizure , family history seizure ( parent sibling ) consequence trauma , stroke , metabolic disturbance . The patient history head trauma associate loss consciousness . The patient current suicidal ideation , history suicidal ideation , history suicide attempt . The patient history major depressive disorder , bipolar disorder , significant mood disorder , schizophrenia psychotic disorder , eat disorder , family history suicide . The patient leave ventricular hypertrophy patient mitral valve prolapse experience mitral valve prolapse syndrome . The patient receive investigational drug within 30 day 5 halflives ( whichever longer ) 1st dose study drug , case new chemical entity , 3 month 5 halflives ( whichever longer ) 1st dose study drug . The patient use monoamine oxidase inhibitor ( MAOIs ) stimulant within 14 day 5 halflives ( whichever longer ) baseline visit . The patient use modafinil armodafinil within 4 week baseline visit . The patient use inducer CYP3A4/5 within 28 day prior study drug administration . The patient use inhibitor CYP3A4/5 within 14 day 5 half life ( whichever longer ) prior study drug administration . The patient know sensitivity idiosyncratic reaction compound present modafinil armodafinil , related compound , metabolite compound list present medication . The patient history clinically significant cutaneous drug reaction , history clinically significant hypersensitivity reaction , include multiple allergy drug reaction Other criterion apply , please contact investigator additional information</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Pediatric Narcolepsy</keyword>
</DOC>